Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 179

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 179
---
 not include 210,832 RSUs that remain subject to vesting.
  
    (4)
    Does not include 1,194 RSUs that remain subject to vesting.
  
    (5)
    Does not include 209,791 RSUs that remain subject to vesting.
  
    (6)
    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the “Master Fund”), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Company  held by the Master Fund and thus may be deemed to beneficially own the securities of the Company held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Company held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Company directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Change
of Control

The
Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.

82

Securities
authorized for issuance under equity compensation plans 

2018
Equity Incentive Plan

Our
2018 Equity Incentive Plan (the “Plan”) provides for equity incentives to be granted to our employees, executive officers
or directors and to key advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not
less than the fair market value of the underlying shares as determined pursuant to the Plan, restricted stock awards, other stock- based
awards, or any combination of the foregoing. The Plan is administered by the Company’s compensation committee or, alternatively,
if there is no compensation committee, the Company’s board of directors. We have reserved 3,000,000 shares of our common stock
for issuance under the Plan, of which 1,187,189 shares have been granted under the Plan as of the date of this Annual Report, of which
1,084,644 remain subject to vesting.

The
following table provides information as of December 31, 2024 about our equity compensation plans and arrangements.

    Plan category 
    Number of securities to be issued upon exercise of outstanding options, warrants and rights  
    Weighted- average exercise price of